Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ: TEM) announced acceptance of 31 abstracts, including one oral presentation, for the AACR Annual Meeting 2026 (April 17–22) in San Diego. The company will present multimodal AI and sequencing research across colorectal, lung, GI, and pan‑cancer studies and host an Exhibitor Spotlight Theater session on April 20.
Tempus (NASDAQ: TEM) launched an automated Active Follow-Up clinical update service on April 13, 2026 to keep genomic reports current with evolving guidelines and approvals.
The service monitors guideline, FDA and patient-context changes and delivers updated therapy recommendations via Hub without requiring a new sample, aiming to support evidence-based, guideline-concordant oncology care.
Tempus (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead (NASDAQ:GILD) to advance oncology R&D using real-world evidence and AI. The agreement gives Gilead enterprise-wide access to Tempus' Lens platform, broader multimodal datasets across multiple indications, and dedicated Tempus analytical services.
This collaboration targets trial design, indication selection, biomarker strategy, and health outcomes analysis to inform clinical decision-making and support oncology pipeline development.
Tempus (NASDAQ: TEM) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16. CFO Jim Rogers will join a fireside discussion on April 14 at 11:45 am ET. A live webcast of the conversation will be available for investors to view.
Tempus (NASDAQ:TEM) and Medtronic announced results from the ALERT trial on April 1, 2026 showing AI-driven EHR clinician notifications improved timely evaluation and treatment for significant aortic stenosis and mitral regurgitation.
The multicenter, cluster-randomized study (2,016 echocardiograms; 765 clinicians; 35 hospitals) met its primary endpoint (win ratio 1.27; P = .007) and showed a 40% relative increase in valve procedures (13.4% vs. 9.6%) within 90 days.
Tempus (NASDAQ: TEM) and Blood Cancer United announced a collaboration to build a large, patient-centered real-world registry for pediatric acute myeloid leukemia (pAML) using Tempus’ olivia app and Lens analytics.
The program will collect longitudinal patient‑reported outcomes, align educational materials to disease subtype and treatment stage, and enable de‑identified data access to support external control arms and accelerate pediatric AML research.
Tempus (NASDAQ: TEM) published a JCO Precision Oncology study (March 11, 2026) showing advanced comprehensive genomic profiling (CGP) features uncover clinically actionable findings missed by limited testing.
The study, in collaboration with The Oncology Institute, found 12% of patients had actionable findings tied to approved therapies identified solely via tumor-normal matching, RNA sequencing, and liquid biopsy reflex.
Authors argue CGP value extends beyond panel size and that guideline specificity on panel composition remains limited.
Tempus (NASDAQ:TEM) announced a multi-year strategic collaboration with Merck on March 3, 2026 to accelerate AI-driven precision medicine across oncology and potentially broader therapeutic areas. Merck will access Tempus’ de-identified multimodal data, Lens Platform, and Workspaces to train AI/ML models and discover precision biomarkers and resistance mechanisms.
The agreement leverages Tempus’ large GPU infrastructure for training-ready datasets, aiming to speed discovery, optimize candidate therapies, and inform rational combination strategies in Merck’s early pipeline.
Tempus (NASDAQ: TEM) will participate in the Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 3 in San Francisco. Founder and CEO Eric Lefkofsky will appear in a fireside chat at 9:15 AM PST.
A live webcast is available via the provided link and a recording will be posted on Tempus' Events page on its Investor Relations website.
Tempus (NASDAQ:TEM) reported strong fourth quarter and full year 2025 results, driven by diagnostics and data growth. Q4 revenue was $367.2M (+83.0% YoY) and full‑year revenue was $1.27B (+83.4% YoY). Gross profit rose to $797.9M for 2025.
The company closed 2025 with >$1.1B Total Remaining Contract Value, 126% net revenue retention, $759.7M in cash and marketable securities, and 2026 guidance of ~$1.59B revenue with ~ $65M Adjusted EBITDA.